Dr. Martens plc (DOCS), the London-listed iconic British footwear brand, has disclosed that its Chief Executive Officer and Chief Financial Officer purchased ordinary shares in the company on 11 November 2026 under its Share Incentive Plan. The transactions, notified to the company on 12 November 2026, were conducted at a price of 63.2 pence per share and triggered the award of an equal number of free Matching Shares to each participating executive. The disclosure was made in accordance with Article 19 of the UK Market Abuse Regulation, underscoring the regulatory transparency obligations applicable to persons discharging managerial responsibility.

Key Points

  • Dr. Martens plc (DOCS) — London Stock Exchange-listed British footwear company
  • CEO Ije Nwokorie and CFO Giles Wilson each purchased Partnership Shares and received an equal allocation of Matching Shares on 11 November 2026
  • Partnership Shares acquired at 63.2 pence per share; Matching Shares awarded at nil consideration on a one-for-one basis
  • Investors may watch for further PDMR participation disclosures as the SIP continues through monthly salary contributions

CEO Ije Nwokorie and CFO Giles Wilson Purchase Shares at 63.2p on 11 November 2026

Chief Executive Officer Ije Nwokorie purchased 238 Partnership Shares at 63.2 pence per share on 11 November 2026 and was simultaneously awarded 238 Matching Shares at no cost under the company's Share Incentive Plan. Chief Financial Officer Giles Wilson purchased 237 Partnership Shares at the same price of 63.2 pence and received a corresponding allocation of 237 Matching Shares, also at nil consideration. Both transactions were conducted through the London Stock Exchange and are classified as initial notifications under UK Market Abuse Regulation requirements. The ordinary shares carry a nominal value of 1 pence each and are identified by ISIN GB00BL6NGV24.

How Dr. Martens' HMRC-Approved Share Incentive Plan Works for Participating Employees

The Share Incentive Plan is an HMRC-approved, all-employee scheme that allows eligible participants to purchase shares in Dr. Martens directly from their monthly salary, referred to as Partnership Shares. The company then grants Matching Shares on a one-for-one basis for every Partnership Share purchased, at no cost to the participating employee. The scheme is designed to align the interests of employees, including senior executives, with those of shareholders by encouraging direct ownership of the company's ordinary shares. Participation by the CEO and CFO reflects engagement with this broader employee ownership structure.

Dr. Martens as a Global Footwear Brand and Its London Stock Exchange Listing

Dr. Martens is a globally recognised British footwear brand best known for its distinctive boots and shoes, sold across international markets. The company is listed on the London Stock Exchange and operates under the ticker DOCS. Its shares are structured as ordinary shares of GBP 0.01 nominal value. The company's Legal Entity Identifier is 213800QPT8YM6NQZPH28. The brand has a broad international retail and wholesale presence, and its revenues are generated through direct-to-consumer and wholesale channels across multiple geographies.

Regulatory Context: Article 19 UK Market Abuse Regulation Obligations

The notifications were made pursuant to Article 19 of the UK Market Abuse Regulation, which requires persons discharging managerial responsibilities to disclose transactions in the issuer's financial instruments within defined timeframes. Both notifications are classified as initial disclosures, confirming no prior amendments exist. Transactions of this nature, while routine in the context of an all-employee share scheme, carry regulatory weight as they provide the market with transparency regarding director shareholding activity. Investors may monitor subsequent monthly SIP disclosures to track ongoing participation levels among the company's senior leadership.